GlassScriptPhysician profile
William L Skinner
NPI 1376657254
$18,245.42
in general payments reported to CMS, 2019-2025
86 companies · $3,509 in 2025
The $3,509 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,139 · 2020: $1,691 · 2021: $2,922 · 2022: $3,686 · 2023: $2,138 · 2024: $161 · 2025: $3,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,225 · Food and Beverage: $1,919 · Education: $497 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,225.00 |
| Food and Beverage | $1,918.87 |
| Education | $497.07 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,513.08 | 2019-2025 | |
| Celgene Corporation | $2,169.09 | 2019-2023 | Pomalyst, Reblozyl |
| Novartis Pharmaceuticals Corporation | $1,049.89 | 2019-2023 | Kisqali, Piqray |
| Amgen INC. | $887.67 | 2019-2023 | Blincyto, Prolia, Evenity |
| Seagen INC. | $860.84 | 2019-2023 | Adcetris, Padcev |
| Janssen Biotech, INC. | $689.12 | 2019-2024 | Erleada, Darzalex, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $665.72 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $640.41 | 2019-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $474.65 | 2019-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $468.41 | 2019-2023 | |
| Astellas Pharma US INC | $407.33 | 2019-2023 | Xtandi |
| Genentech USA, INC. | $354.52 | 2019-2023 | Phesgo, Lunsumio, Rozlytrek |
| Beigene USA, INC. | $266.48 | 2020-2023 | Brukinsa |
| Incyte Corporation | $264.28 | 2019-2023 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $259.21 | 2019-2025 | Datroway |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.